论文部分内容阅读
目的探讨氯沙坦对高血压病合并高尿酸血症(HUA)患者血尿酸(UA)的影响。方法选取2015年1月至2016年1月在佛山市顺德区北滘医院门诊及住院处的符合高血压病合并HUA患者72例,随机分为氯沙坦组和厄贝沙坦组,各36例。分别观察治疗前及治疗24周后两组患者血压、UA等的变化。结果治疗前,两组收缩压(SBP)和舒张压(DBP)及UA比较,差异无统计学意义(P>0.05)。治疗24周后,两组患者SBP、DBP均较本组治疗前下降,差异有统计学意义(P<0.05);两组患者UA都有所下降,但厄贝沙坦组UA治疗前后差异无统计学意义(P>0.05),而氯沙坦组UA较厄贝沙坦组降低,差异有统计学意义(P<0.01)。厄贝沙坦组有1例出现踝关节轻微肿胀,观察1周后肿胀消失。其余病例均未出现高血钾、血管性水肿和低血压等。结论氯沙坦能降低高血压病合并HUA患者的UA水平。
Objective To investigate the effect of losartan on serum uric acid (UA) in hypertensive patients with hyperuricemia (HUA). Methods From January 2015 to January 2016, 72 patients with hypertension complicated with HUA in outpatient and inpatient department of Beibei Hospital, Shunde District, Foshan City were selected and randomly divided into losartan group and irbesartan group, with 36 example. The changes of blood pressure and UA before and 24 weeks after treatment were observed respectively. Results Before treatment, there was no significant difference in SBP, DBP and UA between the two groups (P> 0.05). After 24 weeks of treatment, the SBP and DBP in both groups were significantly lower than those before treatment (P <0.05). The UA in both groups decreased, but there was no significant difference in UA group before and after UA treatment Statistically significant (P> 0.05), while losartan UA was lower than irbesartan group, the difference was statistically significant (P <0.01). One case of irbesartan group showed slight ankle swelling, and one week later, swelling disappeared. The remaining cases did not appear hyperkalemia, angioedema and hypotension. Conclusion Losartan can reduce the UA in hypertensive patients with HUA.